Pesquisar
OKYO Pharma Ltd
OKYOAdicionar à lista de desejos
1.560USD
+0.040+2.63%
Fechamento 08-17 16:00（ET）Cotações atrasadas em 15 min
79.77MValor de mercado
PerdaP/L TTM
Mais detalhes de OKYO Pharma Ltd Empresa
OKYO Pharma Limited is a United Kingdom-based clinical-stage biopharmaceutical company developing therapies for the treatment of dry eye disease (DED) and neuropathic corneal pain (NCP). The Company is focused on the discovery and development of novel molecules to treat neuropathic corneal pain and dry eye disease. Its research program focuses on a novel G Protein-Coupled Receptor (GPCR). The Company’s lead candidate, urcosimod, is a non-steroidal anti-inflammatory and non-opioid analgesic. Urcosimod consists of a 10-mer C-terminal Chemerin sequence, a linker (PEG-8), and Palmitic acid. It has completed a Phase II trial in patients with DED and NCP. The Company also plans to evaluate its potential in benefiting patients with ocular neuropathic pain, uveitis and allergic conjunctivitis. It is also evaluating OK-201, a bovine adrenal medulla (BAM), lipidated-peptide preclinical analogue candidate that is in the developmental stage.
OKYO Pharma Ltd Perfil
Código da empresaOKYO
Nome da EmpresaOKYO Pharma Ltd
Data de listagemJul 17, 2018
CEOJacob (Gary S)
Número de funcionários4
Tipo de títulosOrdinary Share
Fim do ano fiscalJul 17
EndereçoFloor 4, 14/15 Conduit St
CidadeLONDON
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited Kingdom
Código postalW1S 2XJ
Telefone442074952379
Sitehttps://okyopharma.com/
Código da empresaOKYO
Data de listagemJul 17, 2018
CEOJacob (Gary S)
Executivos da empresa OKYO Pharma Ltd
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Raj Patil
Dr. Raj Patil
Chief Scientific Officer
Chief Scientific Officer
23.39K
+28.75%
Dr. Raj Patil
Dr. Raj Patil
Chief Scientific Officer
Chief Scientific Officer
23.39K
+28.75%
Mr. John P. Brancaccio, CPA
Mr. John P. Brancaccio, CPA
Non-Executive Independent Director
Non-Executive Independent Director
10.00K
--
Mr. John P. Brancaccio, CPA
Mr. John P. Brancaccio, CPA
Non-Executive Independent Director
Non-Executive Independent Director
10.00K
--
Dr. Gary S. Jacob, Ph.D.
Dr. Gary S. Jacob, Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
7.00K
--
Dr. Gary S. Jacob, Ph.D.
Dr. Gary S. Jacob, Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
7.00K
--
Mr. Gabriele Marco Antonio Cerrone
Mr. Gabriele Marco Antonio Cerrone
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Ms. Keeren Shah
Ms. Keeren Shah
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Willy Jules Simon
Mr. Willy Jules Simon
Senior Non-Executive Director
Senior Non-Executive Director
--
-100.00%
Mr. Bernard F. Denoyer, CPA
Mr. Bernard F. Denoyer, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Raj Patil
Dr. Raj Patil
Chief Scientific Officer
Chief Scientific Officer
23.39K
+28.75%
Dr. Raj Patil
Dr. Raj Patil
Chief Scientific Officer
Chief Scientific Officer
23.39K
+28.75%
Mr. John P. Brancaccio, CPA
Mr. John P. Brancaccio, CPA
Non-Executive Independent Director
Non-Executive Independent Director
10.00K
--
Mr. John P. Brancaccio, CPA
Mr. John P. Brancaccio, CPA
Non-Executive Independent Director
Non-Executive Independent Director
10.00K
--
Dr. Gary S. Jacob, Ph.D.
Dr. Gary S. Jacob, Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
7.00K
--
Dr. Gary S. Jacob, Ph.D.
Dr. Gary S. Jacob, Ph.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
7.00K
--
Perguntas frequentes
Quem são os cinco principais acionistas de OKYO Pharma Ltd?
Os cinco principais acionistas de OKYO Pharma Ltd são: Dr. Raj Patil
Quantas instituições possuem ações da OKYO Pharma Ltd (OKYO)?
Em 2026Q1, 19 instituições possuíam ações da OKYO Pharma Ltd, com valor de mercado aproximado de 4.78M, representando 9.11% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em 1185385.00.